Sphingomyelin synthase 2 (SGMS2)

Sphingomyelin synthase 2 (SGMS2) is a membrane-bound enzyme responsible for the reversible transfer of the phosphocholine head group from phosphatidylcholine to ceramide, producing sphingomyelin (a key component of cell and Golgi membranes) and diacylglycerol as a side product[1][2][4]. SGMS2 is primarily localized at the plasma membrane and to a lesser extent in the Golgi apparatus[2][4]. By modulating the levels of bioactive lipids such as ceramide and diacylglycerol, SGMS2 regulates signal transduction pathways implicated in cell growth, apoptosis, and membrane structure. It plays a critical role in bone mineralization; pathogenic variants in SGMS2 disrupt normal bone formation and can cause inherited bone fragility syndromes[1][2]. SGMS2 is also implicated in cancer biology, where high expression correlates with enhanced proliferation, reduced apoptosis, increased invasiveness, and metastasis, notably through modulation of pathways such as TGF-β/Smad in breast cancer[3]. No approved drugs currently target SGMS2 directly, and drug-interaction data are lacking, but the enzyme’s role in sphingolipid metabolism makes it a candidate for therapeutic intervention in metabolic, skeletal, and malignant diseases[1][2][3][4].

Other names

Phosphatidylcholine:ceramide cholinephosphotransferase 2SMS2Sphingomyelin synthase 2MGC26963CDLceramide cholinephosphotransferase 2SM synthasesphingomyelin synthase 2

Inhibition or modulation of enzymatic activity regulating sphingomyelin and ceramide levels; Alteration of diacylglycerol and ceramide-mediated signaling pathways